Analysis calls for more research on patient portal development

Researchers identified five main problem categories and key factors contributing to these problems in a review of literature about patient portals.

Published in the Journal of the American Medical Informatics Association, lead author Terese Otte-Trojel, of Erasmus University Rotterdam, and colleagues in both the Netherlands and at the University of California, Berkeley, named the following problem categories featured in current literature:

  • Achieving patient engagement
  • Provider engagement
  • Appropriate data governance
  • Security and interoperability
  • Sustainable business model

About half (45) of the 109 articles proposed solutions, fewer than half of these solutions (18) were implemented, and even fewer (5) were evaluated to generate learning about their effects.

The authors offered recommendations for advancement of the evidence base: “Future research should build on existing evidence, draw on principles from design sciences conveyed in the problem-solving cycle, and seek to produce evidence within various different organizational contexts,” Otte-Trojel and colleagues concluded.

Access the complete study.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.